Mahesh Moolani, MD
Internal Medicine · Owensboro, KYNPI 1124076831
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $837 of the $1,164 with a category attached, or 72.0%. It is spread thinly across 17 manufacturers, the largest accounting for just 18.3%. Reporting peaked in 2019 at $490 and has fallen 90.0% since, to $49 in 2025.
Across 92 payments — averaging $12.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$212
- Novartis$210
- Novo Nordisk$162
- Astellas Pharma US Inc$127
- Sunovion Pharmaceuticals Inc.$87
- AbbVie$68
- plus $297 from 11 others
Across 5 payments — averaging $2580.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$13K
What the payments were for
- Food & beverage$83772%
- Education$32628%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 36 | $212 |
| Novartis | 15 | $210 |
| Novo Nordisk | 11 | $162 |
| Astellas Pharma US Inc | 2 | $127 |
| Sunovion Pharmaceuticals Inc. | 7 | $87 |
| AbbVie | 4 | $68 |
| Bayer | 1 | $53 |
| Supernus Pharmaceuticals, Inc. | 3 | $40 |
| GSK | 2 | $31 |
| Lilly USA, LLC | 2 | $29 |
| Gilead | 1 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Sumitomo Pharma America, Inc. | 2 | $29 |
| Corcept Therapeutics | 1 | $20 |
| Amgen | 1 | $15 |
| AstraZeneca | 1 | $12 |
| Pfizer | 1 | $9 |
How this compares
$1,164 in reported general payments places this provider in the 65th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 860 | $324,816 |
| OzempicSemaglutide | 225 | $231,479 |
| JardianceEmpagliflozin | 195 | $139,296 |
| LinzessLinaclotide | 199 | $126,297 |
| FarxigaDapagliflozin Propanediol | 231 | $115,888 |
| SprycelDasatinib | 12 | $108,696 |
| EnbrelEtanercept | 30 | $83,663 |
| JanuviaSitagliptin Phosphate | 140 | $83,122 |
| RybelsusSemaglutide | 69 | $77,878 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 117 | $69,903 |
| EntrestoSacubitril/Valsartan | 114 | $69,433 |
| TradjentaLinagliptin | 183 | $60,307 |
| Breo ElliptaFluticasone/Vilanterol | 124 | $58,250 |
| GlatopaGlatiramer Acetate | 19 | $46,328 |
| TrulicityDulaglutide | 28 | $39,655 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $9 | $324,816860 claims |
| Novo NordiskOzempic, Rybelsus | $162 | $309,357294 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $31 | $150,575285 claims |
| AbbVieLinzess | $68 | $126,297199 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $12 | $123,685245 claims |
| AmgenEnbrel | $15 | $83,66330 claims |
| NovartisEntresto | $210 | $69,433114 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $29 | $64,27551 claims |
| Astellas Pharma US IncMyrbetriq | $127 | $18,46854 claims |
| Sanofi-aventis U.S. LLCLantus | $29 | $12,314133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Owensboro
- Bernard BuchananOwensboro$185K
- Jeremy LuckettOwensboro$12K
- Fares KhaterWhitesburg$412K
- David ManninoLexington$168K
- John PeppinCynthiana$108K
- Sanjay KaulBrownsville$69K
- John JonesHazard$63K
- Robert SasserLouisville$62K
- Justin LandeDanville$60K
- Sanjiv GuptaGrayson$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.